We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Facial deformations during nasal continuous positive airway pressure therapy.
Journal of Biomechanics 2016 December 9
Obstructive Sleep Apnoea (OSA), characterised by repeated collapse of the pharyngeal airway during sleep, causes cessation of breathing followed by arousal, restoring normality. Continuous Positive Airway Pressure (CPAP) is a non-invasive, effective treatment for OSA where positive pressure is applied to the airway through a mask, maintaining patency. Nasal masks are commonly used, contacting the face across the upper lip, sides of the nose and the nasal bridge. Despite health benefits, therapy compliance is sub-optimal, often due to poor mask fit and discomfort. Masks have been designed to conform to the facial profile, but have not taken into account facial deformations. The nature of facial deformations while undergoing CPAP therapy is unknown. This study investigates the facial deformations experienced by a patient while undergoing nasal CPAP therapy. Magnetic Resonance Imaging (MRI) scans of the face were acquired of participants in the reference configuration and while undergoing CPAP therapy. The CPAP scan volume was registered onto the reference volume prior to surface generation for each state. Perpendicular deformation was measured from the reference facial profile to the deformed profile. Large facial deformations were measured at the sides of the nose (4.6±1.6mm) and the upper lip (4.9±1.8mm) with much smaller deformations at the nasal bridge (2.4±0.2mm). When normalised by applied load and tissue thickness, no difference was found. These findings and techniques can be used to consider facial deformation in the development of future nasal CPAP masks to improve comfort and compliance to therapy.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app